May 22 |
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
|
Apr 5 |
Piper downgrades Achilles to neutral, cites latest data
|
Apr 4 |
Achilles Therapeutics GAAP EPS of -$0.46 misses by $0.32
|
Apr 4 |
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
|
Apr 4 |
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
|
Feb 9 |
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
|
Feb 5 |
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
|
Jan 24 |
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?
|